These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 9849412)

  • 1. Methodological and statistical issues of quality of life (QoL) and economic evaluation in cancer clinical trials: report of a workshop.
    Neymark N; Kiebert W; Torfs K; Davies L; Fayers P; Hillner B; Gelber R; Guyatt G; Kind P; Machin D; Nord E; Osoba D; Revicki D; Schulman K; Simpson K
    Eur J Cancer; 1998 Aug; 34(9):1317-33. PubMed ID: 9849412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Costs of quality-of-life research in Southwest Oncology Group trials.
    Moinpour CM
    J Natl Cancer Inst Monogr; 1996; (20):11-6. PubMed ID: 8750461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Quality of life in oncological studies].
    Flechtner H
    Onkologie; 2001 Sep; 24 Suppl 5():22-7. PubMed ID: 11600809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quality of life in oncology trials: a clinical guide.
    Movsas B
    Semin Radiat Oncol; 2003 Jul; 13(3):235-47. PubMed ID: 12903013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic analysis alongside clinical trials. Revisiting the methodological issues.
    Drummond MF; Davies L
    Int J Technol Assess Health Care; 1991; 7(4):561-73. PubMed ID: 1778701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic evaluation alongside cancer trials: methodological and practical aspects.
    Bonsel GJ; Rutten FF; Uyl-de Groot CA
    Eur J Cancer; 1993; 29A Suppl 7():S10-4. PubMed ID: 8312059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Taking quality of life into account in health economic analyses.
    Weeks J
    J Natl Cancer Inst Monogr; 1996; (20):23-7. PubMed ID: 8750463
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Health-related quality of life, satisfaction, and economic outcome measures in studies of prostate cancer screening and treatment, 1990-2000.
    McNaughton-Collins M; Walker-Corkery E; Barry MJ
    J Natl Cancer Inst Monogr; 2004; (33):78-101. PubMed ID: 15504921
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deriving a compound quality of life measure from the EORTC-QLQ-C30/LC13 instrument for use in economic evaluations of lung cancer clinical trials.
    Bagust A; Barraza-Llorens M; Philips Z
    Eur J Cancer; 2001 Jun; 37(9):1081-8. PubMed ID: 11378337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A review of health-utility data for osteoarthritis: implications for clinical trial-based evaluation.
    Ruchlin HS; Insinga RP
    Pharmacoeconomics; 2008; 26(11):925-35. PubMed ID: 18850762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic analyses in clinical trials for cooperative groups: operational considerations.
    Bennett CL; Waters TM
    Cancer Invest; 1997; 15(5):448-53. PubMed ID: 9316627
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conducting economic evaluations alongside multinational clinical trials: toward a research consensus.
    Reed SD; Anstrom KJ; Bakhai A; Briggs AH; Califf RM; Cohen DJ; Drummond MF; Glick HA; Gnanasakthy A; Hlatky MA; O'Brien BJ; Torti FM; Tsiatis AA; Willan AR; Mark DB; Schulman KA
    Am Heart J; 2005 Mar; 149(3):434-43. PubMed ID: 15864231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Report from a National Cancer Institute (USA) workshop on quality of life assessment in cancer clinical trials.
    Nayfield SG; Ganz PA; Moinpour CM; Cella DF; Hailey BJ
    Qual Life Res; 1992 Jun; 1(3):203-10. PubMed ID: 1363776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating health-related quality-of-life studies in paediatric populations: some conceptual, methodological and developmental considerations and recent applications.
    De Civita M; Regier D; Alamgir AH; Anis AH; Fitzgerald MJ; Marra CA
    Pharmacoeconomics; 2005; 23(7):659-85. PubMed ID: 15987225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quality of life in children and adolescents with cystic fibrosis: implications for optimizing treatments and clinical trial design.
    Abbott J; Gee L
    Paediatr Drugs; 2003; 5(1):41-56. PubMed ID: 12513105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generic health-related quality-of-life assessment in children and adolescents: methodological considerations.
    Ravens-Sieberer U; Erhart M; Wille N; Wetzel R; Nickel J; Bullinger M
    Pharmacoeconomics; 2006; 24(12):1199-220. PubMed ID: 17129075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Measurement and valuation of quality of life in economic appraisal of cancer treatment.
    Uyl-de Groot CA; Rutten FF; Bonsel GJ
    Eur J Cancer; 1994; 30A(1):111-7. PubMed ID: 8142152
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical importance, statistical significance and the assessment of economic and quality-of-life outcomes.
    Drummond M; O'Brien B
    Health Econ; 1993 Oct; 2(3):205-12. PubMed ID: 8275165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Statistical issues in quality-of-life assessment.
    Chow SC; Ki FY
    J Biopharm Stat; 1996 Mar; 6(1):37-48. PubMed ID: 8838777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic evaluations of treatments for systemic fungal infections: a systematic review of the literature.
    Dixon S; McKeen E; Tabberer M; Paisley S
    Pharmacoeconomics; 2004; 22(7):421-33. PubMed ID: 15137881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.